FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:BORA-VCP

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: BORA-VCP
FusionPDB ID: 10040
FusionGDB2.0 ID: 10040
HgeneTgene
Gene symbol

BORA

VCP

Gene ID

79866

7415

Gene nameBORA aurora kinase A activatorvalosin containing protein
SynonymsC13orf34CDC48|TERA|p97
Cytomap

13q21.33

9p13.3

Type of geneprotein-codingprotein-coding
Descriptionprotein aurora borealistransitional endoplasmic reticulum ATPase15S Mg(2+)-ATPase p97 subunitTER ATPase
Modification date2020031320200327
UniProtAcc

Q6PGQ7

Main function of 5'-partner protein: FUNCTION: Required for the activation of AURKA at the onset of mitosis. {ECO:0000269|PubMed:16890155}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000464754, ENST00000377815, 
ENST00000390667, 
ENST00000358901, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 4 X 3=3611 X 13 X 3=429
# samples 514
** MAII scorelog2(5/36*10)=0.473931188332412
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(14/429*10)=-1.61555082055458
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: BORA [Title/Abstract] AND VCP [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: BORA [Title/Abstract] AND VCP [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)BORA(73303232)-VCP(35064282), # samples:1
Anticipated loss of major functional domain due to fusion event.BORA-VCP seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BORA-VCP seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BORA-VCP seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BORA-VCP seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BORA-VCP seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneVCP

GO:0006302

double-strand break repair

10855792|22120668

TgeneVCP

GO:0006974

cellular response to DNA damage stimulus

16140914|22120668|23042605

TgeneVCP

GO:0016567

protein ubiquitination

22120668

TgeneVCP

GO:0030433

ubiquitin-dependent ERAD pathway

17872946

TgeneVCP

GO:0030970

retrograde protein transport, ER to cytosol

15215856

TgeneVCP

GO:0031334

positive regulation of protein complex assembly

18775313

TgeneVCP

GO:0032436

positive regulation of proteasomal ubiquitin-dependent protein catabolic process

9452483

TgeneVCP

GO:0036503

ERAD pathway

25088257

TgeneVCP

GO:0045732

positive regulation of protein catabolic process

11483959|18775313

TgeneVCP

GO:0090263

positive regulation of canonical Wnt signaling pathway

28689657

TgeneVCP

GO:1903006

positive regulation of protein K63-linked deubiquitination

22970133

TgeneVCP

GO:1903007

positive regulation of Lys63-specific deubiquitinase activity

22970133



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:73303232/chr9:35064282)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across BORA (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across VCP (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000390667BORAchr1373303232+ENST00000358901VCPchr935064282-3148250102094694

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000390667ENST00000358901BORAchr1373303232+VCPchr935064282-0.0044626590.9955374

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for BORA-VCP

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
BORAchr1373303232VCPchr93506428225080LASPSVFKSTKLPDEEESLNEVGYDD

Top

Potential FusionNeoAntigen Information of BORA-VCP in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BORA-VCP_73303232_35064282.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BORA-VCPchr1373303232chr935064282250HLA-B35:03LPDEEESL0.92250.96361119
BORA-VCPchr1373303232chr935064282250HLA-B35:08LPDEEESL0.88180.9421119
BORA-VCPchr1373303232chr935064282250HLA-B35:04LPDEEESL0.74640.9841119
BORA-VCPchr1373303232chr935064282250HLA-B35:02LPDEEESL0.74640.9841119
BORA-VCPchr1373303232chr935064282250HLA-A02:22KLPDEEESL0.98060.71631019
BORA-VCPchr1373303232chr935064282250HLA-A02:67KLPDEEESL0.97680.81341019
BORA-VCPchr1373303232chr935064282250HLA-A02:30KLPDEEESL0.97680.81341019
BORA-VCPchr1373303232chr935064282250HLA-A02:24KLPDEEESL0.97680.81341019
BORA-VCPchr1373303232chr935064282250HLA-A02:60KLPDEEESL0.97630.76131019
BORA-VCPchr1373303232chr935064282250HLA-A02:11KLPDEEESL0.97450.84731019
BORA-VCPchr1373303232chr935064282250HLA-A02:27KLPDEEESL0.97090.73881019
BORA-VCPchr1373303232chr935064282250HLA-A02:13KLPDEEESL0.97020.7611019
BORA-VCPchr1373303232chr935064282250HLA-A02:04KLPDEEESL0.96360.71291019
BORA-VCPchr1373303232chr935064282250HLA-A02:16KLPDEEESL0.96180.75861019
BORA-VCPchr1373303232chr935064282250HLA-A02:21KLPDEEESL0.94670.89151019
BORA-VCPchr1373303232chr935064282250HLA-A02:38KLPDEEESL0.92190.7221019
BORA-VCPchr1373303232chr935064282250HLA-A02:29KLPDEEESL0.80480.81321019
BORA-VCPchr1373303232chr935064282250HLA-A02:20KLPDEEESL0.78570.81811019
BORA-VCPchr1373303232chr935064282250HLA-A02:35KLPDEEESL0.75750.83451019
BORA-VCPchr1373303232chr935064282250HLA-B35:12LPDEEESL0.74640.9841119
BORA-VCPchr1373303232chr935064282250HLA-B39:10LPDEEESL0.74240.94231119
BORA-VCPchr1373303232chr935064282250HLA-A02:01KLPDEEESL0.97680.81341019
BORA-VCPchr1373303232chr935064282250HLA-A02:07KLPDEEESL0.97590.79961019
BORA-VCPchr1373303232chr935064282250HLA-A02:05KLPDEEESL0.96080.56591019
BORA-VCPchr1373303232chr935064282250HLA-C01:17KLPDEEESL0.95090.96231019
BORA-VCPchr1373303232chr935064282250HLA-C07:13KLPDEEESL0.60630.97811019
BORA-VCPchr1373303232chr935064282250HLA-C01:30KLPDEEESL0.47880.97131019
BORA-VCPchr1373303232chr935064282250HLA-B35:09LPDEEESL0.74640.9841119
BORA-VCPchr1373303232chr935064282250HLA-C04:03KLPDEEESL0.99640.8551019
BORA-VCPchr1373303232chr935064282250HLA-C01:03KLPDEEESL0.98980.9571019
BORA-VCPchr1373303232chr935064282250HLA-A02:03KLPDEEESL0.97470.79141019
BORA-VCPchr1373303232chr935064282250HLA-C01:02KLPDEEESL0.95740.95941019
BORA-VCPchr1373303232chr935064282250HLA-A02:14KLPDEEESL0.94740.80051019
BORA-VCPchr1373303232chr935064282250HLA-A02:06KLPDEEESL0.94670.89151019
BORA-VCPchr1373303232chr935064282250HLA-B15:30KLPDEEESL0.69540.8381019

Top

Potential FusionNeoAntigen Information of BORA-VCP in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BORA-VCP_73303232_35064282.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BORA-VCPchr1373303232chr935064282250DRB1-0801SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0801ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0803SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0805SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0805ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0806SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0806ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0810SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0810ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0812SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0812ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0814SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0816SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0816ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0818SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0818ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0822SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0822ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0823SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0826SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0826ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0827SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0829SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0829ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0829PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-0829LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-0833SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0835SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0836SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0838SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0839SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0839ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0840SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-0840ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-0840PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1154SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1303SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1303ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1303PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1303LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1304SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-13101SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-13101ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-13101PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-13101LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1310SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1310ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1310PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1310LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1312SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1312ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1312PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1313SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1313ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1321SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1321ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1330SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1330ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1332SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1332ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1333SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1333ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1338SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1338ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1348SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1348ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1349SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1349ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1355SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1355ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1358SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1358ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1358LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1358PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1365SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1365ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1366SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1366ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1366PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1375SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1375ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1376SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1381SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1381ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1381LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1381PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1388SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1388ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1388PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1388LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1389SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1389ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1389LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1389PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1390SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1390ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1390PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1390LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1393SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1394SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1394ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1394PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1394LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1395SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1395ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1395PSVFKSTKLPDEEES318
BORA-VCPchr1373303232chr935064282250DRB1-1395LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1413SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1413ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1422SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1425SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1433SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1462SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1462ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1463SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1469SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1469ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1470SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1473SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1473ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1473LASPSVFKSTKLPDE015
BORA-VCPchr1373303232chr935064282250DRB1-1474SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1474ASPSVFKSTKLPDEE116
BORA-VCPchr1373303232chr935064282250DRB1-1478SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1485SPSVFKSTKLPDEEE217
BORA-VCPchr1373303232chr935064282250DRB1-1485ASPSVFKSTKLPDEE116

Top

Fusion breakpoint peptide structures of BORA-VCP

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2437FKSTKLPDEEESLNBORAVCPchr1373303232chr935064282250

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BORA-VCP

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2437FKSTKLPDEEESLN-8.62545-8.73885
HLA-B14:023BVN2437FKSTKLPDEEESLN-3.26321-4.29851
HLA-B52:013W392437FKSTKLPDEEESLN-6.23413-6.34753
HLA-B52:013W392437FKSTKLPDEEESLN-4.55402-5.58932
HLA-A24:025HGA2437FKSTKLPDEEESLN-8.62578-8.73918
HLA-A24:025HGA2437FKSTKLPDEEESLN-6.438-7.4733
HLA-B44:053DX82437FKSTKLPDEEESLN-5.68484-5.79824
HLA-B44:053DX82437FKSTKLPDEEESLN-3.64855-4.68385
HLA-A02:016TDR2437FKSTKLPDEEESLN-5.14764-6.18294

Top

Vaccine Design for the FusionNeoAntigens of BORA-VCP

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
BORA-VCPchr1373303232chr9350642821019KLPDEEESLAAATTACCAGATGAGGAAGAGTCCTTG
BORA-VCPchr1373303232chr9350642821119LPDEEESLTTACCAGATGAGGAAGAGTCCTTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
BORA-VCPchr1373303232chr935064282015LASPSVFKSTKLPDECTCGCCAGTCCTTCTGTTTTTAAATCAACAAAATTACCAGATGAG
BORA-VCPchr1373303232chr935064282116ASPSVFKSTKLPDEEGCCAGTCCTTCTGTTTTTAAATCAACAAAATTACCAGATGAGGAA
BORA-VCPchr1373303232chr935064282217SPSVFKSTKLPDEEEAGTCCTTCTGTTTTTAAATCAACAAAATTACCAGATGAGGAAGAG
BORA-VCPchr1373303232chr935064282318PSVFKSTKLPDEEESCCTTCTGTTTTTAAATCAACAAAATTACCAGATGAGGAAGAGTCC

Top

Information of the samples that have these potential fusion neoantigens of BORA-VCP

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
N/ABORA-VCPchr1373303232ENST00000390667chr935064282ENST00000358901CN311554

Top

Potential target of CAR-T therapy development for BORA-VCP

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to BORA-VCP

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to BORA-VCP

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource